8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Feb 24, 2026·SEC
Cytokinetics, Incorporated(CYTK)Earnings, Financials & Key Ratios
CYTK•NASDAQ
$74.84
$9.22B mkt cap·Price updated May 6, 2026
AboutCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Show more
- Revenue$88M+376.6%
- EBITDA-$603M-14.4%
- Net Income-$785M-33.2%
- EPS (Diluted)-6.54-24.3%
- Gross Margin88.5%+105.1%
- EBITDA Margin-684.44%+76.0%
- Operating Margin-695.44%+76.0%
- Net Margin-891.6%+72.1%
- ROIC-305.27%-209.3%
- Interest Coverage-7.56-30.0%
CYTK Key Insights
Cytokinetics, Incorporated (CYTK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 43.9% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CYTK Price & Volume
Cytokinetics, Incorporated (CYTK) stock price & volume — 10-year historical chart
Loading chart...
CYTK Growth Metrics
Cytokinetics, Incorporated (CYTK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.88%
5 Years9.54%
3 Years-2.36%
TTM450.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-29.06%
Return on Capital
10 Years-38.02%
5 Years-46.56%
3 Years-55.12%
Last Year-50.1%
CYTK Recent Earnings
Cytokinetics, Incorporated (CYTK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 5, 2026EPS
$1.67
Est $1.67
+0.0%
Revenue
$19M
Est $9M
+127.2%
Q1 2026
Feb 24, 2026EPS
$1.50
Est $1.48
-1.4%
Revenue
$18M
Est $7M
+156.3%
Q4 2025
Nov 5, 2025EPS
$1.54
Est $1.59
+3.1%
Revenue
$2M
Est $8M
-75.9%
Q3 2025
Aug 7, 2025EPS
$1.12
Est $1.34
+16.4%
Revenue
$67M
Est $2M
+3131.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.67vs $1.67+0.0% | $19Mvs $9M+127.2% |
| Q1 2026 | Feb 24, 2026 | $1.50vs $1.48-1.4% | $18Mvs $7M+156.3% |
| Q4 2025 | Nov 5, 2025 | $1.54vs $1.59+3.1% | $2Mvs $8M-75.9% |
| Q3 2025 | Aug 7, 2025 | $1.12vs $1.34+16.4% | $67Mvs $2M+3131.1% |
Based on last 12 quarters of dataView full earnings history →
CYTK Peer Comparison
Cytokinetics, Incorporated (CYTK) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 TENX | 71M | 12.02 | -10.45 | -45.03% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 |
Compare CYTK vs Peers
Cytokinetics, Incorporated (CYTK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CYTK Income Statement
Cytokinetics, Incorporated (CYTK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 13.37M | 31.5M | 26.87M | 55.83M | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M | 105.81M |
| Revenue Growth % | -87.44% | 135.64% | -14.71% | 107.79% | 26.15% | 34.3% | -92.04% | 145.34% | 376.56% | 450.6% |
| Cost of Goods Sold | 90.3M | 89.14M | 86.13M | 96.95M | 159.94M | 240.81M | 330.12M | 339.41M | 10.13M | 10.22M |
| COGS % of Revenue | 675.46% | 282.96% | 320.55% | 173.66% | 227.09% | 254.59% | 4384.1% | 1837.22% | 11.5% | - |
| Gross Profit | -76.93M▲ 0% | -57.63M▲ 25.1% | -59.26M▼ 2.8% | -41.12M▲ 30.6% | -89.51M▼ 117.7% | -146.22M▼ 63.4% | -322.59M▼ 120.6% | -320.93M▲ 0.5% | 77.91M▲ 124.3% | 95.6M▲ 0% |
| Gross Margin % | -575.46% | -182.96% | -220.55% | -73.66% | -127.09% | -154.59% | -4284.1% | -1737.22% | 88.5% | 90.34% |
| Gross Profit Growth % | -283.12% | 25.08% | -2.82% | 30.6% | -117.66% | -63.36% | -120.61% | 0.51% | 124.28% | - |
| Operating Expenses | 36.47M | 31.28M | 39.61M | 52.82M | 96.8M | 177.98M | 173.61M | 215.31M | 690.17M | 735.84M |
| OpEx % of Revenue | 272.8% | 99.3% | 147.42% | 94.61% | 137.45% | 188.16% | 2305.6% | 1165.5% | 783.94% | - |
| Selling, General & Admin | 36.47M | 31.28M | 39.61M | 52.82M | 96.8M | 177.98M | 173.61M | 215.31M | 284.27M | 331.8M |
| SG&A % of Revenue | 272.8% | 99.3% | 147.42% | 94.61% | 137.45% | 188.16% | 2305.6% | 1165.5% | 322.89% | - |
| Research & Development | 90.3M | 89.14M | 86.13M | 96.95M | 159.94M | 240.81M | 330.12M | 339.41M | 405.9M | 408.85M |
| R&D % of Revenue | 675.46% | 282.96% | 320.55% | 173.66% | 227.09% | 254.59% | 4384.1% | 1837.22% | 461.05% | - |
| Other Operating Expenses | -90.3M | -89.14M | -86.13M | -96.95M | -159.94M | -240.81M | -330.12M | -339.41M | 0 | -1.84M |
| Operating Income | -113.4M▲ 0% | -88.92M▲ 21.6% | -98.87M▼ 11.2% | -93.94M▲ 5.0% | -186.31M▼ 98.3% | -324.2M▼ 74.0% | -496.2M▼ 53.1% | -536.25M▼ 8.1% | -612.26M▼ 14.2% | -640.25M▲ 0% |
| Operating Margin % | -848.26% | -282.26% | -367.97% | -168.27% | -264.54% | -342.75% | -6589.71% | -2902.72% | -695.44% | -605.06% |
| Operating Income Growth % | -706.82% | 21.59% | -11.19% | 4.98% | -98.33% | -74.01% | -53.05% | -8.07% | -14.17% | - |
| EBITDA | -111.5M | -87.68M | -97.57M | -92.11M | -176.68M | -315.8M | -484.31M | -526.72M | -602.57M | -632.6M |
| EBITDA Margin % | -834.05% | -278.33% | -363.16% | -164.99% | -250.86% | -333.87% | -6431.78% | -2851.13% | -684.44% | -597.84% |
| EBITDA Growth % | -673.89% | 21.36% | -11.29% | 5.6% | -91.81% | -78.75% | -53.36% | -8.76% | -14.4% | -13.75% |
| D&A (Non-Cash Add-back) | 1.9M | 1.24M | 1.29M | 1.83M | 9.64M | 8.4M | 11.89M | 9.53M | 9.69M | 7.64M |
| EBIT | -110.79M | -84.72M | -94.33M | -88.61M | -185.98M | -337.8M | -468.58M | -503.01M | -784.96M | -572.99M |
| Net Interest Income | -14.39M | -17.37M | -22.82M | -33.35M | -29M | -39.81M | -30.04M | -34.98M | -55.45M | -46.2M |
| Interest Income | 2.6M | 4.19M | 4.54M | 5.33M | 331K | 11.34M | 27.63M | 51.53M | 48.42M | 34.72M |
| Interest Expense | 17M | 21.56M | 27.36M | 38.68M | 29.33M | 51.16M | 57.67M | 86.51M | 103.87M | 66.4M |
| Other Income/Expense | -14.39M | -17.37M | -22.82M | -33.35M | -29M | -64.75M | -30.04M | -53.28M | -172.7M | -189.37M |
| Pretax Income | -127.79M▲ 0% | -106.29M▲ 16.8% | -121.69M▼ 14.5% | -127.29M▼ 4.6% | -215.31M▼ 69.2% | -388.95M▼ 80.6% | -526.24M▼ 35.3% | -589.53M▼ 12.0% | -784.96M▼ 33.2% | -829.61M▲ 0% |
| Pretax Margin % | -955.94% | -337.41% | -452.93% | -228% | -305.72% | -411.21% | -6988.63% | -3191.11% | -891.6% | -784.02% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -127.79M▲ 0% | -106.29M▲ 16.8% | -121.69M▼ 14.5% | -127.29M▼ 4.6% | -215.31M▼ 69.2% | -388.95M▼ 80.6% | -526.24M▼ 35.3% | -589.53M▼ 12.0% | -784.96M▼ 33.2% | -829.61M▲ 0% |
| Net Margin % | -955.94% | -337.41% | -452.93% | -228% | -305.72% | -411.21% | -6988.63% | -3191.11% | -891.6% | -784.02% |
| Net Income Growth % | -876.7% | 16.83% | -14.49% | -4.6% | -69.15% | -80.65% | -35.3% | -12.03% | -33.15% | -34.84% |
| Net Income (Continuing) | -127.79M | -106.29M | -121.69M | -127.29M | -215.31M | -388.95M | -526.24M | -589.53M | -784.96M | -829.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.59▲ 0% | -1.95▲ 24.7% | -2.59▼ 32.8% | -1.97▲ 23.9% | -2.80▼ 42.1% | -4.33▼ 54.6% | -5.45▼ 25.9% | -5.26▲ 3.5% | -6.54▼ 24.3% | -6.73▲ 0% |
| EPS Growth % | -764.1% | 24.71% | -32.82% | 23.94% | -42.13% | -54.64% | -25.87% | 3.49% | -24.33% | -29.06% |
| EPS (Basic) | -2.59 | -1.95 | -2.59 | -1.97 | -2.80 | -4.33 | -5.45 | -5.26 | -6.54 | - |
| Diluted Shares Outstanding | 49.4M | 54.42M | 57.58M | 64.52M | 76.89M | 89.83M | 96.52M | 111.98M | 120.1M | 123.27M |
| Basic Shares Outstanding | 49.4M | 54.42M | 57.58M | 64.52M | 76.89M | 89.83M | 96.52M | 111.98M | 120.02M | 123.27M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CYTK Balance Sheet
Cytokinetics, Incorporated (CYTK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 274.3M | 207.67M | 233.75M | 474.22M | 535.67M | 795.19M | 628.05M | 1.11B | 916.98M | 839.47M |
| Cash & Short-Term Investments | 268.89M | 198.73M | 225.11M | 464.06M | 471.64M | 782.58M | 614.82M | 1.08B | 882.22M | 818.55M |
| Cash Only | 125.21M | 42.26M | 36.43M | 82.98M | 112.67M | 65.58M | 113.02M | 94.86M | 882.22M | 129.84M |
| Short-Term Investments | 143.69M | 156.47M | 188.68M | 381.07M | 358.97M | 717M | 501.8M | 981.16M | 0 | 688.71M |
| Accounts Receivable | 1.11M | 6.79M | 5.16M | 4.42M | 51.82M | 147K | 1.28M | 16.65M | 0 | 6.83M |
| Days Sales Outstanding | 30.36 | 78.62 | 70.14 | 28.9 | 268.56 | 0.57 | 62.19 | 328.96 | - | 14.7 |
| Inventory | 0 | -6.79M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 154K |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 1.38 |
| Other Current Assets | 4.29M | 0 | 0 | 0 | 0 | 12.46M | 0 | 15.28M | 34.75M | 13.93M |
| Total Non-Current Assets | 20.52M | 3.5M | 56.06M | 59.58M | 305.65M | 219.59M | 196.26M | 293.73M | 507.56M | 434.01M |
| Property, Plant & Equipment | 3.57M | 3.2M | 13.41M | 16.27M | 146.41M | 163.19M | 147.74M | 140.97M | 155.17M | 156.98M |
| Fixed Asset Turnover | 3.75x | 9.83x | 2.00x | 3.43x | 0.48x | 0.58x | 0.05x | 0.13x | 0.57x | 0.69x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 16.52M | 0 | 42.65M | 36.95M | 152.05M | 46.71M | 40.53M | 145.06M | 335.05M | 1.06B |
| Other Non-Current Assets | 429K | 300K | 0 | 6.36M | 7.19M | 9.69M | 8M | 7.71M | 17.34M | 71.02M |
| Total Assets | 294.81M▲ 0% | 211.18M▼ 28.4% | 289.81M▲ 37.2% | 533.8M▲ 84.2% | 841.32M▲ 57.6% | 1.01B▲ 20.6% | 824.32M▼ 18.8% | 1.4B▲ 70.0% | 1.42B▲ 1.6% | 1.27B▲ 0% |
| Asset Turnover | 0.05x | 0.15x | 0.09x | 0.10x | 0.08x | 0.09x | 0.01x | 0.01x | 0.06x | 0.08x |
| Asset Growth % | 73.27% | -28.37% | 37.24% | 84.19% | 57.61% | 20.62% | -18.77% | 70.04% | 1.63% | -17.16% |
| Total Current Liabilities | 32.44M | 22.19M | 26.02M | 31.2M | 71.86M | 84.62M | 102.68M | 179.67M | 202.45M | 199.19M |
| Accounts Payable | 5.25M | 3.76M | 8.16M | 8.05M | 21.09M | 25.61M | 21.51M | 20.37M | 105.61M | 24.71M |
| Days Payables Outstanding | 21.23 | 15.41 | 34.58 | 30.31 | 48.12 | 38.82 | 23.78 | 21.9 | 3.81K | 1.51K |
| Short-Term Debt | 0 | 2.61M | 0 | 0 | 0 | 958K | 10.08M | 11.52M | 41.18M | 65.77M |
| Deferred Revenue (Current) | 9.57M | 15.76M | 0 | 0 | 0 | 0 | 0 | 52.37M | 0 | 4.61M |
| Other Current Liabilities | 11.36M | 66K | 9.47M | 12.84M | 16.47M | 22.89M | 39.81M | 21.11M | 36.55M | 107.06M |
| Current Ratio | 8.45x | 9.36x | 8.98x | 15.20x | 7.45x | 9.40x | 6.12x | 6.17x | 4.53x | 4.53x |
| Quick Ratio | 8.45x | 9.66x | 8.98x | 15.20x | 7.45x | 9.40x | 6.12x | 6.17x | 4.53x | 4.53x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.49K |
| Total Non-Current Liabilities | 152.52M | 163.05M | 274.73M | 389.22M | 525.6M | 1.04B | 1.11B | 1.36B | 1.88B | 1.9B |
| Long-Term Debt | 31.78M | 39.81M | 129.26M | 135.71M | 142.84M | 609.62M | 607.37M | 645.6M | 1.12B | 975.75M |
| Capital Lease Obligations | 0 | 771K | 2.19M | 440K | 112.23M | 126.89M | 120.43M | 112.58M | 107.97M | 329.65M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 105.75M | 122.47M | 143.28M | 166.07M | 183.53M | 301.55M | 380.16M | 599.19M | 657.76M | 2.88B |
| Total Liabilities | 184.97M | 185.24M | 300.75M | 420.42M | 597.46M | 1.12B | 1.21B | 1.54B | 2.08B | 2.1B |
| Total Debt | 31.78M | 42.41M | 136.07M | 138.94M | 269.93M | 750.3M | 755.77M | 788.68M | 1.28B | 1.04B |
| Net Debt | -93.43M | 157K | 99.64M | 55.95M | 157.26M | 684.72M | 642.75M | 693.82M | 402.02M | 911.67M |
| Debt / Equity | 0.29x | 1.64x | - | 1.23x | 1.11x | - | - | - | - | -1.26x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.65x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.44x |
| Interest Coverage | -6.52x | -3.93x | -3.45x | -2.29x | -6.34x | -6.60x | -8.13x | -5.81x | -7.56x | -8.63x |
| Total Equity | 109.84M▲ 0% | 25.93M▼ 76.4% | -10.94M▼ 142.2% | 113.38M▲ 1136.7% | 243.86M▲ 115.1% | -107.9M▼ 144.2% | -386.32M▼ 258.0% | -135.37M▲ 65.0% | -659.63M▼ 387.3% | -826.57M▲ 0% |
| Equity Growth % | 16.41% | -76.39% | -142.17% | 1136.69% | 115.08% | -144.25% | -258.04% | 64.96% | -387.27% | -4683.33% |
| Book Value per Share | 2.22 | 0.48 | -0.19 | 1.76 | 3.17 | -1.20 | -4.00 | -1.21 | -5.49 | -6.71 |
| Total Shareholders' Equity | 109.84M | 25.93M | -10.94M | 113.38M | 243.86M | -107.9M | -386.32M | -135.37M | -659.63M | -826.57M |
| Common Stock | 54K | 768.76M | 59K | 70K | 84K | 94K | 102K | 118K | 123K | 124K |
| Retained Earnings | -646.08M | -743.32M | -865.02M | -992.31M | -1.21B | -1.59B | -2.11B | -2.7B | -3.49B | -3.69B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 343K | 500K | 679K | 149K | -869K | -3.59M | -10K | 2.4M | 630K | -1.61M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CYTK Cash Flow Statement
Cytokinetics, Incorporated (CYTK) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -101.76M | -101.22M | -90.91M | 8.94M | -142.52M | -299.52M | -414.33M | -395.89M | -510.01M | -510.01M |
| Operating CF Margin % | -761.21% | -321.31% | -338.35% | 16.02% | -202.37% | -316.65% | -5502.43% | -2142.96% | -579.3% | - |
| Operating CF Growth % | -375.16% | 0.53% | 10.18% | 109.84% | -1693.67% | -110.15% | -38.33% | 4.45% | -28.83% | -163.11% |
| Net Income | -127.79M | -106.29M | -121.69M | -127.29M | -215.31M | -388.95M | -526.24M | -589.53M | -784.96M | -829.61M |
| Depreciation & Amortization | 1.92M | 1.24M | 1.29M | 1.83M | 2.28M | 5.81M | 11.89M | 9.53M | 10.13M | 11.2M |
| Stock-Based Compensation | 9.03M | 9.76M | 10.76M | 17.62M | 26.83M | 47.85M | 72.06M | 97.84M | 0 | 88.63M |
| Deferred Taxes | -67K | 0 | 0 | -573K | 2.84M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 14.66M | 17.01M | 22.62M | 28.24M | 32.38M | 60.48M | 24.86M | 50.6M | 300.45M | 236.36M |
| Working Capital Changes | 487K | -22.94M | -3.89M | 89.12M | 8.46M | -24.7M | 3.09M | 35.66M | -35.63M | -30.43M |
| Change in Receivables | -1.09M | -1.12M | 1.62M | 743K | -47.4M | 56.67M | -1.14M | -15.37M | -1.11M | -4.82M |
| Change in Inventory | -1.4M | 4.91M | 0 | 1.48M | 0 | 0 | 0 | 0 | 0 | -3.57M |
| Change in Payables | 1.46M | -1.49M | 4.4M | -110K | 1.05M | 4.52M | -3.48M | -4.48M | 2.66M | 8.76M |
| Cash from Investing | -65.83M | 5.13M | -74.71M | -196.51M | -147.78M | -262.13M | 239.25M | -553.1M | 16.67M | 56.2M |
| Capital Expenditures | -2.88M | -889K | -2.62M | -11.05M | -48.87M | -11.34M | -1.42M | -3.91M | -24.81M | -25.07M |
| CapEx % of Revenue | 21.52% | 2.82% | 9.75% | 19.8% | 69.39% | 11.98% | 18.8% | 21.14% | 28.18% | - |
| Acquisitions | 0 | 14K | 0 | 185.46M | 98.91M | 250.8M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -62.95M | 14K | 0 | -185.46M | -98.91M | -250.8M | 0 | 0 | -5M | 0 |
| Cash from Financing | 225.92M | 13.13M | 159.79M | 234.12M | 319.98M | 516.17M | 221.32M | 930.61M | 524.46M | 527.47M |
| Debt Issued (Net) | 1.26M | 9.9M | 135.57M | 0 | 0 | 334.66M | -858K | -9.62M | 490.95M | 493.83M |
| Equity Issued (Net) | 119.78M | 0 | 36.21M | 225.11M | 312.05M | 17.54M | 164.23M | 706.84M | 35.98M | 28.33M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32.68M |
| Other Financing | 104.87M | 3.23M | -11.99M | 9.02M | 7.93M | 163.96M | 57.94M | 233.38M | -2.47M | 5.32M |
| Net Change in Cash | 58.33M▲ 0% | -82.95M▼ 242.2% | -5.82M▲ 93.0% | 46.55M▲ 899.5% | 29.68M▼ 36.2% | -45.48M▼ 253.2% | 46.22M▲ 201.6% | -18.17M▼ 139.3% | 30.4M▲ 267.3% | 58.9M▲ 0% |
| Free Cash Flow | -104.64M▲ 0% | -102.1M▲ 2.4% | -93.53M▲ 8.4% | -2.11M▲ 97.7% | -191.39M▼ 8975.1% | -310.85M▼ 62.4% | -415.75M▼ 33.7% | -399.8M▲ 3.8% | -534.82M▼ 33.8% | -548.92M▲ 0% |
| FCF Margin % | -782.73% | -324.13% | -348.09% | -3.78% | -271.76% | -328.64% | -5521.24% | -2164.1% | -607.48% | -518.76% |
| FCF Growth % | -395.7% | 2.42% | 8.4% | 97.75% | -8975.11% | -62.41% | -33.75% | 3.84% | -33.77% | -34.1% |
| FCF per Share | -2.12 | -1.88 | -1.62 | -0.03 | -2.49 | -3.46 | -4.31 | -3.57 | -4.45 | -4.45 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.95x | 0.75x | -0.07x | 0.66x | 0.77x | 0.79x | 0.67x | 0.65x | 0.66x |
| Interest Paid | 2.13M | 2.88M | 4.06M | 0 | 0 | 0 | 10.29M | 0 | 0 | 0 |
| Taxes Paid | 1K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CYTK Key Ratios
Cytokinetics, Incorporated (CYTK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -125.16% | -156.57% | -1622.88% | -248.5% | -120.54% | -572.15% | - | - | - | 139.66% |
| Return on Invested Capital (ROIC) | -238.62% | -313.79% | -129.19% | -54.61% | -48.99% | -49.73% | -89.33% | -98.71% | -305.27% | -305.27% |
| Gross Margin | -575.46% | -182.96% | -220.55% | -73.66% | -127.09% | -154.59% | -4284.1% | -1737.22% | 88.5% | 90.34% |
| Net Margin | -955.94% | -337.41% | -452.93% | -228% | -305.72% | -411.21% | -6988.63% | -3191.11% | -891.6% | -784.02% |
| Debt / Equity | 0.29x | 1.64x | - | 1.23x | 1.11x | - | - | - | - | -1.26x |
| Interest Coverage | -6.52x | -3.93x | -3.45x | -2.29x | -6.34x | -6.60x | -8.13x | -5.81x | -7.56x | -8.63x |
| FCF Conversion | 0.80x | 0.95x | 0.75x | -0.07x | 0.66x | 0.77x | 0.79x | 0.67x | 0.65x | 0.66x |
| Revenue Growth | -87.44% | 135.64% | -14.71% | 107.79% | 26.15% | 34.3% | -92.04% | 145.34% | 376.56% | 450.6% |
CYTK SEC Filings & Documents
Cytokinetics, Incorporated (CYTK) SEC filings — annual & quarterly reports (10-K, 10-Q)
CYTK Frequently Asked Questions
Cytokinetics, Incorporated (CYTK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cytokinetics, Incorporated (CYTK) reported $105.8M in revenue for fiscal year 2025. This represents a 829% increase from $11.4M in 2002.
Cytokinetics, Incorporated (CYTK) grew revenue by 376.6% over the past year. This is strong growth.
Cytokinetics, Incorporated (CYTK) reported a net loss of $829.6M for fiscal year 2025.
Dividend & Returns
Cytokinetics, Incorporated (CYTK) had negative free cash flow of $548.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More CYTK
Cytokinetics, Incorporated (CYTK) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates